The company have substantially improved this course of the new solution for amyloid heart disease, utilizing Attruby. Initial trial data suggests potential benefits for those affected by the debilitating illness. The focus underscores researchers’ dedication to managing critical patient demands in a heart disease space. Attruby: BridgeBio's Nove